Prevalence and cardiometabolic impact of mild autonomous cortisol secretion in primary aldosteronism: a systematic review and meta-analysis.

J HypertensJul 16, 2026 (epub)
Clinical ResearchEndocrinology

Naseem Eisa, Mira Khoury

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the prevalence of mild autonomous cortisol secretion (MACS) in patients with primary aldosteronism (PA) and its cardiometabolic effects. Among 2356 patients from 14 studies, the pooled prevalence of MACS was found to be 26.2%. Patients with MACS had a 60% increased risk of cardiovascular events compared to those without.

Key findings

  • Pooled prevalence of MACS in PA was 26.2% (95% CI: 24.1-28.4).
  • Patients with MACS had 60% higher odds of cardiovascular events (OR 1.60; 95% CI: 1.07-2.38).
  • MACS was associated with a 37% increased risk of type 2 diabetes mellitus (OR 1.37; 95% CI: 1.00-1.86).
  • No significant association was found between MACS and obesity (OR 1.10; P = 0.411).

Why it matters

Understanding the prevalence and impact of MACS in PA is crucial for clinicians, as it highlights the need for routine screening and risk assessment. This can inform management strategies to mitigate cardiovascular and metabolic complications in affected patients.

Source

PubMed · PMID 42554261

Published in J Hypertens. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Endocrinology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.